Given the fact that schwannomas, as many other cancers, are not always responsive to anti-EGFR treatment [48], our study suggests that Pak1 and/or Ack1 may prove critical therapeutic targets for schwannomas. This evidence concerns the gene PAK1 and schwannoma.